IGF Oncology LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2004-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.igfoncology.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome
Phase 1
Terminated
- Conditions
- Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicAnemia, Refractory, With Excess of Blasts
- Interventions
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- IGF Oncology, LLC
- Target Recruit Count
- 2
- Registration Number
- NCT03175978
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Regions Cancer Care Center, Saint Paul, Minnesota, United States
Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R
Phase 1
Completed
- Conditions
- Brain CancerGynecologic CancersMelanomaGastrointestinal CancersThoracic CancersBreast CancerGenitourinary CancersHead and Neck Cancers
- Interventions
- Drug: IGF-Methotrexate conjugate
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- IGF Oncology, LLC
- Target Recruit Count
- 92
- Registration Number
- NCT02045368
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
News
No news found